Donate to Illuminate TSF 5K Contact TSF
Facebook Logo Twitter Logo Youtube Logo Instagram Logo LinkedIn Logo TikTok Logo Blue Sky Logo

Archives: Research Summaries

Eculizumab monotherapy for NMOSD: Data from PREVENT and its open-label extension

Eculizumab monotherapy for NMOSD: Data from PREVENT and its open-label extension

Journal: Multiple Sclerosis Journal; September 9, 2021

Author(s): Sean J Pittock, Kazuo Fujihara, Jacqueline Palace, Achim Berthele, Ho Jin Kim, Celia Oreja-Guevara, Ichiro Nakashima, Michael Levy, Shulian Shang, Marcus Yountz, Larisa Miller, Róisín Armstrong, Dean M Wingerchuk; PREVENT Study Group

Potential long-term benefits of eculizumab alone in NMOSD treatment

Eculizumab in Aquaporin-4-Positive Neuromyelitis Optica Spectrum Disorder

Eculizumab in Aquaporin-4-Positive Neuromyelitis Optica Spectrum Disorder

Journal: The New England Journal of Medicine; August 15, 2019

Author(s): Sean J Pittock, Achim Berthele, Kazuo Fujihara, Ho Jin Kim, Michael Levy, Jacqueline Palace, Ichiro Nakashima, Murat Terzi, Natalia Totolyan, Shanthi Viswanathan, Kai-Chen Wang, Amy Pace, Kenji P Fujita, Róisín Armstrong, Dean M Wingerchuk

Clinical trial of eculizumab treatment in NMOSD patients testing positive for aquaporin-4 antibodies

International Delphi Consensus on the Management of AQP4-IgG+ NMOSD: Recommendations for Eculizumab, Inebilizumab, and Satralizumab

International Delphi Consensus on the Management of AQP4-IgG+ NMOSD: Recommendations for Eculizumab, Inebilizumab, and Satralizumab

Journal: Neurology Neuroimmunology & Neuroinflammation; May 31, 2023

Author(s): Friedemann Paul, Romain Marignier, Jacqueline Palace, Georgina Arrambide, Nasrin Asgari, Jeffrey L. Bennett, Bruce Anthony Campbell Cree, Jérôme De Sèze, Kazuo Fujihara, Ho Jin Kim, Rebecca Hornby, Saif Huda, Najib Kissani, Ingo Kleiter, Satoshi Kuwabara, Marco Lana-Peixoto, Lisa Law, M. Isabel Leite, Lekha Pandit, Sean J. Pittock, Chao Quan, Sudarshini Ramanathan, Dalia Rotstein, Albert Saiz, Douglas Kazutoshi Sato, Adi Vaknin-Dembinsky

Recommendations for management of NMOSD with eculizumab, inebilizumab, and satralizumab: Consensus among international experts

Long-Term Safety and Efficacy of Eculizumab in Aquaporin-4 IgG-Positive NMOSD

Long-Term Safety and Efficacy of Eculizumab in Aquaporin-4 IgG-Positive NMOSD

Journal: Annals of Neurology; February 14, 2021

Author(s): Dean M Wingerchuk, Kazuo Fujihara, Jacqueline Palace, Achim Berthele, Michael Levy, Ho Jin Kim, Ichiro Nakashima, Celia Oreja-Guevara, Kai-Chen Wang, Larisa Miller, Shulian Shang, Guido Sabatella, Marcus Yountz, Sean J Pittock; PREVENT Study Group

Long-term safety and efficacy of eculizumab in NMOSD patients testing positive for aquaporin-4 antibodies

Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2/3 trial

Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2/3 trial

Journal: The Lancet; September 5, 2019

Author(s): Bruce A C Cree, Jeffrey L Bennett, Ho Jin Kim, Brian G Weinshenker, Sean J Pittock, Dean M Wingerchuk, Kazuo Fujihara, Friedemann Paul, Gary R Cutter, Romain Marignier, Ari J Green, Orhan Aktas, Hans-Peter Hartung, Fred D Lublin, Jorn Drappa, Gerard Barron, Soraya Madani, John N Ratchford, Dewei She, Daniel Cimbora, Eliezer Katz; N-MOmentum study investigators

Clinical trial paper of Inebilizumab for the treatment of NMOSD